Novel pharmaceuticals

Founded in 2001, with headquarters in Taiwan and a fully-owned subsidiary in Beijing, China, our company is a research-based and product-driven pharmaceutical company focusing on the discovery, development and commercialization of novel pharmaceuticals. Our company carries out innovative RandD using regional advantages to discover and develop first-in-class or best-in-class new chemical entities (NCEs) with global IP protection. The company achieves growth driven by global vision and strategy: 1) Focus on internal discovery and supplement with in-licensing for a sustainable pipeline 2) Conduct multinational trials under US FDAw ith highest integrity and create maximum value 3) Utilize Class 1.1 New Drug to accelerate development and commercialization in China 4) Share risk and reward through alliances and partnering The company has raised US$172 million in five rounds since its inception including the IPO in Taiwan in January 2014 and is listed at the Taipei Exchange through its holding company. The company's current pipeline includes three best-in-class/first-in- class NCEs: the antibiotic, Taigexyn®; a hematology/ oncology agent, Burixafor; and an antiviral for hepatitis C, Furaprevir.